Anika Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Anika Therapeutics (ANIK) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 Revenue Guidance
August 8, 2024 4:27 PM EDTAnika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.17, $0.10 better than the analyst estimate of $0.07. Revenue for the quarter came in at $41.9 million versus the consensus estimate of $40.77 million.
GUIDANCE:
Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus... More
